PUT - SPRINTER OPEN END - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 11:24:56 15/05/2024 pm IST | ||
| 7.26 EUR | -13.16% |
|
| Current month | -21.09% | ||
| 1 month | -33.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 7.26 | -13.16% |
| 14/24/14 | 8.36 | -0.36% |
| 13/24/13 | 8.39 | -2.33% |
| 10/24/10 | 8.59 | -1.15% |
| 09/24/09 | 8.69 | -0.69% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 11:24 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU8LNN |
| ISIN | DE000VU8LNN4 |
| Date issued | 14/06/2023 |
| Strike | 312.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.63 € |
|---|---|
| Lowest since issue | 0.89 € |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
235.3
USD
Average target price
285.9
USD
Spread / Average Target
+21.50%
- Stock Market
- Certificates
- Certificat